|
HOWL | Werewolf Therapeutics, Inc. |
|
|
HOWL | Werewolf Therapeutics, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.69 |
| Leverage | 55.21% |
| Market Cap | $ 59.8m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -72.9m |
| Margin | -39848.60% |
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapies designed to boost the bodys immune system for the treatment of cancer. The company is headquartered in Cambridge, Massachusetts.